Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › peg-IFN

peg-IFN

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of peg-IFN

10 trials tracked of peg-IFN: 6 in phase 3 or 4.

10Trials tracked
6Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 5 Phase 2 4
  1. Phase 4 Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B Completed
  2. Phase 3 SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection Completed
  3. Phase 3 Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043) Completed
  4. Phase 3 Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045) Completed
  5. Phase 3 Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044) Completed
  6. Phase 3 Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies Completed
Show 4 more trials
  1. Phase 2 Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia Completed
  2. Phase 2 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection Completed
  3. Phase 2 Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection Completed
  4. Phase 2 A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
DOC1021 vaccine with SOC showed favorable 12-month OS in newly-diagnosed glioblastoma patients
Oncology RCT
DOC1021 vaccine with SOC showed favorable 12-month OS in newly-diagnosed glioblastoma patients A New Brain Cancer Vaccine Shows Promise Where Other Treatments Fail
This Phase I clinical study evaluated DOC1021 (dubodencel) integrated with standard of care (SOC) in newly-diagnosed and recurrent glioblast…
A new type of personalized vaccine, added to standard treatment, was safe and linked to significantly longer survival for patients with a no…
medRxiv Apr 10, 2026